Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Troubleshooting in advanced VATS procedures

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Diabetic kidney disease is a frequent and costly complication to type 2 diabetes. After many years with a lack of successful trials there are now significant developments that will change treatment, guidelines and future outcome. Since the last two decades blockade of the renin-angiotensin system (RAS) is standard treatment, but new antidiabetic treatments have shown potential for kidney protection. After cardiovascular outcome studies with glucagon-like peptide (GLP-1) receptor agonists it is evident that drugs like liraglutide, semaglutide and dulaglutide can reduce albuminuria levels and progression to macroalbuminuria. At present, a renal outcome trial with semaglutide is ongoing which will provide more evidence on the drug class in the future. The sodium glucose co-transporter 2 (SGLT2) inhibitor class has also demonstrated effects beyond glucose-lowering, as the drugs can reduce blood pressure, albuminuria and loss of renal function. In the first renal outcome study the SGLT2 inhibitor canagliflozin was found to reduce the risk of hard renal outcome with 30%. SGLT2 inhibition is now recommended in type 2 diabetes with chronic kidney disease. Renal outcome studies testing additional SGLT2 inhibitors and the GLP-1 receptor agonist semaglutide will report in the coming future potentially providing more and much needed options for treatment.

Original languageEnglish
JournalAnnals of Translational Medicine
Volume9
Issue number8
Pages (from-to)716
ISSN2305-5839
DOIs
Publication statusPublished - Apr 2021

    Research areas

  • Albuminuria, diabetic kidney disease, glomerular filtration rate, dialysis, type 2 diabetes

ID: 66944957